Sudhir S Kushwaha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8082284/publications.pdf

Version: 2024-02-01

687363 580821 27 736 13 25 citations h-index g-index papers 27 27 27 912 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation. Circulation, 2007, 116, 2726-2733.	1.6	162
2	Sirolimus as Primary Immunosuppression Attenuates Allograft Vasculopathy With Improved Late Survival and Decreased Cardiac Events After Cardiac Transplantation. Circulation, 2012, 125, 708-720.	1.6	105
3	Long-Term Sirolimus for PrimaryÂlmmunosuppression in HeartÂTransplantÂRecipients. Journal of the American College of Cardiology, 2018, 71, 636-650.	2.8	81
4	Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients. European Heart Journal, 2008, 29, 2742-2750.	2.2	54
5	Sirolimus As Primary Immunosuppressant Reduces Left Ventricular Mass and Improves Diastolic Function of the Cardiac Allograft. Transplantation, 2008, 86, 1395-1400.	1.0	45
6	Incidence of Malignancies in Patients Treated With Sirolimus Following HeartÂTransplantation. Journal of the American College of Cardiology, 2019, 73, 2676-2688.	2.8	38
7	Clinical Implications of Intracoronary Imaging in Cardiac Allograft Vasculopathy. Circulation: Cardiovascular Imaging, 2015, 8, .	2.6	31
8	Postcardiotomy ECMO Support after High-risk Operations in Adult Congenital Heart Disease. Congenital Heart Disease, 2016, 11, 751-755.	0.2	30
9	Proximal thoracic aorta dimensions after continuous-flow left ventricular assist device implantation: Longitudinal changes and relation to aortic valve insufficiency. Journal of Heart and Lung Transplantation, 2016, 35, 423-432.	0.6	27
10	No Major Neurologic Complications With Sirolimus Use in Heart Transplant Recipients. Mayo Clinic Proceedings, 2009, 84, 330-332.	3.0	24
11	Diastolic Pulmonary Gradient as a Predictor of Right Ventricular Failure After Left Ventricular Assist Device Implantation. Journal of the American Heart Association, 2019, 8, e012073.	3.7	21
12	Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis. Transplantation, 2018, 102, 1909-1913.	1.0	18
13	Heart-After-Liver Transplantation Attenuates Rejection of Cardiac Allografts in Sensitized Patients. Journal of the American College of Cardiology, 2021, 77, 1331-1340.	2.8	18
14	Predictors and Outcomes of Renal Replacement Therapy After Left Ventricular Assist Device Implantation. Mayo Clinic Proceedings, 2019, 94, 1003-1014.	3.0	13
15	Importance of Routine Antihuman/Leukocyte Antibody Monitoring. Circulation, 2017, 136, 1350-1352.	1.6	12
16	Impact of Sirolimus as a Primary Immunosuppressant on Myocardial Fibrosis and Diastolic Function Following Heart Transplantation. Journal of the American Heart Association, 2021, 10, e018186.	3.7	11
17	International Analysis of LVAD Point-of-Care Versus Plasma INR: A Multicenter Study. ASAIO Journal, 2018, 64, e161-e165.	1.6	7
18	Incidence, Risk Factors, and Outcomes of Stroke Following Cardiac Transplantation. Stroke, 2021, 52, e720-e724.	2.0	7

#	Article	IF	Citations
19	Left Ventricular Hemodynamics and Relationship With Myocardial Recovery and Optimization in Patients Supported on CF-LVAD Therapy. Journal of Cardiac Failure, 2022, 28, 799-806.	1.7	6
20	Peripheral microvascular dysfunction is associated with plaque progression and adverse longâ€term outcomes in heart transplant patients. ESC Heart Failure, 2021, 8, 5266-5274.	3.1	5
21	Epidemiology, risk factors, and association of antifungal prophylaxis on early invasive fungal infection in heart transplant recipients. Transplant Infectious Disease, 2021, 23, e13714.	1.7	5
22	Sirolimus-Based Immunosuppression Is Associated with Decreased Incidence of Post-Transplant Lymphoproliferative Disorder after Heart Transplantation: A Double-Center Study. Journal of Clinical Medicine, 2022, 11, 322.	2.4	5
23	Circulating progenitor cells are associated with plaque progression and long-term outcomes in heart transplant patients. Cardiovascular Research, 2022, 118, 1703-1712.	3.8	4
24	Physiology of Continuousâ€Flow Left Ventricular Assist Device Therapy. , 2021, 12, 2731-2767.		3
25	Intraoperative transesophageal echocardiographic guidance of total artificial heart implantation. Journal of Heart and Lung Transplantation, 2014, 33, 454-457.	0.6	2
26	Pulmonary Pressure Assessment with the Total Artificial Heart. ASAIO Journal, 2018, 64, e34-e36.	1.6	2
27	Malignancy among adult heart transplant recipients following patientâ€ŧailored dosing of antiâ€ŧhymocyte globulin: a retrospective, nested caseâ€control study of individualized dosing. Transplant International, 2021, 34, 2175-2183.	1.6	O